Rapid progression of advanced "hormone-resistant" prostate cancer during palliative treatment with progestins for cancer cachexia

Journal of Pain and Symptom Management

Volumn 25, Issue 5, 2003, Pages 481-484

  Tassinari, Davide ^a,c   Fochessati, Francesca ^a   Panzini, Ilaria ^a   Poggi, Barbara ^a   Sartori, Sergio ^b   Ravaioli, Alberto ^a  

^a City Hospital   (Italy)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^c NONE   (Italy)

Author keywords

Cancer cachexia; Megestrol acetate; Progestins; Prostate cancer

Indexed keywords

AMINOGLUTETHIMIDE; BICALUTAMIDE; FLUTAMIDE; GESTAGEN; GOSERELIN; HYDROCORTISONE; LEUPRORELIN; MEGESTROL ACETATE; METHYLPREDNISOLONE; MITOXANTRONE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; CACHEXIA; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PAIN; CANCER RECURRENCE; CANCER RISK; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG WITHDRAWAL; HORMONE RESISTANCE; HUMAN; MALE; PALLIATIVE THERAPY; PROSTATE CANCER; WASTING SYNDROME; WITHDRAWAL SYNDROME;

EID: 0037405297     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(03)00043-5     Document Type: Article

References (16)

1. Nelson K.A. The cancer anorexia-cachexia syndrome. Semin Oncol. 27(1):2000;64-68.
2. Davis M.P., Dickerson D. Cachexia and anorexia. cancer's covert killer Support Care Cancer. 8:2000;180-187.
3. Mantovani G., Maccio A., Lai P.et al. Cytokyne involvement in cancer anorexia/cachexia. role of megestrol acetate and medroxy-progesterone acetate on cytokine down-regulation and improvements on clinical symptoms Crit Rev Oncog. 9:1998;99-106.
4. Gagnon B., Bruera E. A review of the drug treatment of cachexia associated with cancer. Drugs. 55:1998;675-688.
5. Maltoni M., Nanni O., Scarpi E.et al. High-dose progestins for the treatment of cancer anorexia-cachexia syndrome. a systematic review of randomized clinical trials Ann Oncol. 12(3):2001;289-300.
6. Erlichman C, Loprinzi CL. Hormonal therapies. In: DeVita VT Jr, Hellman S, Rosenberg SA. Cancer. Principles and practice of oncology, 6th edition. Lippincott Williams and Wilkins 2001:478-488.
7. Goktas S., Crawford E.D. Optimal hormone therapy for advanced prostatic carcinoma. Semin Oncol. 26(2):1999;162-173.
8. Small J.E., Vogelzang N.J. Second line hormonal therapy for advanced prostate cancer. a shifting paradigm J Clin Oncol. 15:1997;382-388.
9. Dawson NA. Hormonal therapy for prostate cancer: what you need to know. Alexandria, Virginia: American Society of Clinical Oncology Eds. 1998;368-372.
10. Jenster G. The role of androgen receptor in the development and progression of prostate cancer. Semin Oncol. 26(4):1999;407-421.
11. Bruchovsky N., Rennie P.S., Coldman A.J.et al. Effect of antiandrogen withdrawal on stem cell composition of the Shionigi carcinoma. Cancer Res. 50:1990;2275-2282.
12. Daliani D., Papandreou C.N. Markers of androgen-independent progression of prostatic carcinoma. Semin Oncol. 26(4):1999;399-406.
13. Taplin M.E., Bubley G.J., Shuster T.D.et al. Mutation of the androgen receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med. 332:1995;1393-1398.
14. Dawson N.A., McLeod D.G. Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer. expansion of the antiandrogen withdrawal syndrome J Urol. 153(6):1995;1946-1947.
15. Wehbe T.W., Stein B.S., Akerley W.L. Prostate-specific antigen response to withdrawal of megestrol acetate in a patient with hormone-refractory prostate cancer. Mayo Clin Proc. 72(10):1997;932-934.
16. Burch P.A., Loprinzi C.L. Prostate-specific antigen decline after withdrawal of low-dose megestrol acetate. J Clin Oncol. 17(3):1999;1087-1088.